Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of mitochondria source mc-COX2 as potential marker in CLL

A technology of mc-cox2 and mitochondria, applied in the field of biomedicine, can solve problems such as poor heterogeneity and poor prognosis, and achieve important clinical value and application prospects

Pending Publication Date: 2020-11-13
JIANGSU PROVINCE HOSPITAL THE FIRST AFFILIATED HOSPITAL WITH NANJING MEDICAL UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The heterogeneity of CLL is poor, some patients can survive without progression, but other patients with high risk factors have a poor prognosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of mitochondria source mc-COX2 as potential marker in CLL
  • Application of mitochondria source mc-COX2 as potential marker in CLL
  • Application of mitochondria source mc-COX2 as potential marker in CLL

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] The present invention proposes the application of mitochondrial-derived circular RNA: mc-COX2 as a potential biomarker in chronic lymphocytic leukemia.

[0023] Further, the circular RNA: mc-COX2 is hsa_circ_0089762.

[0024] Further, the application of diagnosis and prognosis evaluation of chronic lymphocytic leukemia can be realized by detecting the expression level of mitochondrial-derived circRNA.

Embodiment 2

[0026] The invention proposes the application of the reagent for detecting the expression level of mc-COX2 in patients with chronic lymphocytic leukemia in the diagnosis of chronic lymphocytic leukemia, and / or the prognosis evaluation of patients with chronic lymphocytic leukemia.

[0027] The reagents include specific primers used to detect mc-COX2 using SYBR Green.

[0028] The specific primers used for the detection of mc-COX2 are PCR amplification primers shown in SEQ ID NO.2 and SEQ ID NO.3;

[0029] SEQ ID NO.2 upstream primer sequence: 5'-CATGTGCCATGTCGCCTG-3';

[0030] The downstream primer sequence of SEQ ID NO.3: 5'-CGCCATCATCCTAGTCCTCA-3'.

Embodiment 3

[0032] The present invention also proposes a prognostic kit for chronic lymphocytic leukemia, including specific primers used for detecting mc-COX2, the specific primers used for detecting mc-COX2 are SEQ ID NO.2 and SEQ ID NO .3 PCR amplification primers;

[0033] SEQ ID NO.2 upstream primer sequence: 5'-CATGTGCCATGTCGCCTG-3';

[0034] The downstream primer sequence of SEQ ID NO.3: 5'-CGCCATCATCCTAGTCCTCA-3'.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a molecular marker mc-COX2 for diagnosing CLL, a reagent and a kit for detecting the expression level of mc-COX2 in a chronic lymphocytic leukemia patient, and a tool for diagnosing and evaluating CLL. The mc-COX2 is highly expressed in a CLL patient and closely related to the expression level of TP53; the total survival rate of mc-COX2 high-expression patients is obviouslylower than that of mc-COX2 low-expression patients, the survival time is 157 months and 74 months respectively, the mc-COX2 expression in the CLL patient is detected through the reagent, the kit and the tool for diagnosing and evaluating the CLL, and the prognosis evaluation of the CLL patient can be realized so that a corresponding positive coping treatment strategy is given, and the applicationhas important clinical value and application prospect.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to the application of mitochondrial-derived circular RNA: mc-COX2 as a potential biomarker in chronic lymphocytic leukemia. Background technique [0002] Chronic lymphocytic leukemia (CLL) is the most common incurable B-cell neoplasm in Western countries, with variable clinical outcomes and difficult differential diagnosis. In my country, the incidence of CLL is on the rise with the aging population, westernization of lifestyle and improvement of clinical diagnosis ability. CLL has poor heterogeneity, and some patients can survive without progression, but other patients with high-risk factors have a poor prognosis. Because the clinical outcome of CLL is variable and the differential diagnosis is difficult, in order to improve the diagnosis and prognosis evaluation of CLL, it is urgent to understand its underlying molecular mechanism and identify new and effective new biomarkers. Conten...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6886
CPCC12Q1/6886C12Q2600/158C12Q2600/178C12Q2600/118
Inventor 李建勇金晖伍紫娟孙汉东王露桥顾丹灵
Owner JIANGSU PROVINCE HOSPITAL THE FIRST AFFILIATED HOSPITAL WITH NANJING MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com